Takayasu Arteritis (TA) is a rare, debilitating large vessel vasculitis occurring in patients of all ages, including infants, but the disease most commonly presents in the third decade. Diagnosis is often delayed and consequently TA is associated with significant morbidity and mortality. Accurate methods of monitoring disease activity or damage are lacking and currently rely on a combination of clinical features, blood inflammatory markers, and imaging modalities. In this report we describe a case of a 14-year-old boy with childhood-onset TA who, despite extensive negative investigations, did indeed have on-going active large vessel vasculitis with fatal outcome. Postmortem analysis demonstrated more extensive and active disease than originally identified. This report illustrates and discusses the limitations of current modalities for the detection and monitoring of disease activity and damage in large vessel vasculitis. Clinicians must be aware of these limitations and challenges if we are to strive for better outcomes in TA. 1. Introduction Takayasu Arteritis (TA) is a large vessel vasculitis of unknown aetiology that affects the aorta and its branches. The cause is unknown, but genetic contribution to disease susceptibility is increasingly recognised [1], whilst suggested links with tuberculosis infection remain unproven [2]. Diagnosis is often considerably delayed: in a recent paediatric classification criteria exercise, the mean time from symptom onset to diagnosis was 1.3 years (SD ± 1.6 years) [3]. Even when the diagnosis is secured, challenges occur in distinguishing between the acute or “active” phase of the illness and the chronic, stenotic phase when symptoms or signs are the result of tissue ischaemia from progressive arterial narrowing [4]. It is important to identify active disease since this requires immunosuppressive treatment, but it is unclear whether immunosuppression is effective in the late stage of the disease when a risk-benefit balance must be made [5]. Revascularisation procedures, such as angioplasty and/or stenting, or more invasive surgical interventions such as aortic bypass grafting are commonly required to provide relief from symptomatic ischaemia but are associated with significant life threatening risks and morbidity and are not completely effective in all cases [6, 7]. Moreover the risk of restenosis is high, particularly if the disease is active at the time of surgery [8–11]. We present a case that highlights the difficulties clinicians face in relation to the diagnosis and monitoring of large vessel vasculitis. 2.
References
[1]
K. A. Morishita, K. Rosendahl, and P. A. Brogan, “Familial Takayasu arteritis—a pediatric case and a review of the literature,” Pediatric Rheumatology, vol. 9, article 6, 2011.
[2]
L. Arnaud, E. Cambau, I. Brocheriou et al., “Absence of Mycobacterium tuberculosis in arterial lesions from patients with Takayasu's arteritis,” Journal of Rheumatology, vol. 36, no. 8, pp. 1682–1685, 2009.
[3]
N. Ruperto, S. Ozen, A. Pistorio et al., “EULAR/PRINTO/PRES criteria for Henoch-Sch?nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterisation,” Annals of the Rheumatic Diseases, vol. 69, no. 5, pp. 790–797, 2010.
[4]
K. Maksimowicz-McKinnon, T. M. Clark, and G. S. Hoffman, “Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients,” Arthritis and Rheumatism, vol. 56, no. 3, pp. 1000–1009, 2007.
[5]
C. Mukhtyar, L. Guillevin, M. C. Cid et al., “EULAR recommendations for the management of large vessel vasculitis,” Annals of the Rheumatic Diseases, vol. 68, no. 3, pp. 318–323, 2009.
[6]
S. A. Rao, K. R. Mandalam, V. R. Rao et al., “Takayasu arteritis: initial and long-term follow-up in 16 patients after percutaneous transluminal angioplasty of the descending thoracic and abdominal aorta,” Radiology, vol. 189, no. 1, pp. 173–179, 1993.
[7]
H. J. Kim, C.-S. Lee, J. S. Kim et al., “Outcomes after endovascular treatment of symptomatic patients with Takayasu's arteritis,” Interventional Neuroradiology, vol. 17, no. 2, pp. 252–260, 2011.
[8]
G. S. Kerr, C. W. Hallahan, J. Giordano et al., “Takayasu arteritis,” Annals of Internal Medicine, vol. 120, no. 11, pp. 919–929, 1994.
[9]
J. W. Son, K. K. Koh, Q. Dang, I. S. Choi, and E. K. Shin, “Recurrent restenosis following stent and rotational atherectomy of coronary artery stenosis in Takayasu's arteritis,” International Journal of Cardiology, vol. 65, no. 3, pp. 295–300, 1998.
[10]
J. Amano and A. Suzuki, “Coronary artery involvement in Takayasu's arteritis: collective review and guideline for surgical treatment,” Journal of Thoracic and Cardiovascular Surgery, vol. 102, no. 4, pp. 554–560, 1991.
[11]
R. Pajari, P. Hekali, and P.-T. Harjola, “Treatment of Takayasu's arteritis: an analysis of 29 operated patients,” Thoracic and Cardiovascular Surgeon, vol. 34, no. 3, pp. 176–181, 1986.
[12]
L. A. Clarke, Y. Hong, D. Eleftheriou et al., “Endothelial injury and repair in systemic vasculitis of the young,” Arthritis and Rheumatism, vol. 62, no. 6, pp. 1770–1780, 2010.
[13]
R. Watts, A. Al-Taiar, J. Mooney, D. Scott, and A. MacGregor, “The epidemiology of Takayasu arteritis in the UK,” Rheumatology, vol. 48, no. 8, pp. 1008–1011, 2009.
[14]
B. K. Sharma, S. Jain, and B. D. Radotra, “An autopsy study of Takayasu arteritis in India,” International Journal of Cardiology, vol. 66, supplement 1, pp. S85–S91, 1998.
[15]
S. Sager, S. Yilmaz, M. Ozhan et al., “F-18 Fdg PET/CT findings of a patient with Takayasu arteritis before and after therapy,” Molecular Imaging and Radionuclide Therapy, vol. 21, pp. 32–34, 2012.
[16]
Y. Cheng, N. Lv, Z. Wang, B. Chen, and A. Dang, “18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis,” Clinical and Experimental Rheumatology, vol. 31, no. 1, supplement 75, pp. S22–S27, 2013.
[17]
M. Papa, F. De Cobelli, E. Baldissera et al., “Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity,” American Journal of Roentgenology, vol. 198, no. 3, pp. W279–W284, 2012.
[18]
W. A. Schmidt, “Imaging in vasculitis,” Best Practice & Research Clinical Rheumatology, vol. 27, pp. 107–118, 2013.
[19]
F. P. Zhu, S. Luo, Z. J. Wang, Z. Y. Jin, L. J. Zhang, and G. M. Lu, “Takayasu arteritis: imaging spectrum at multidetector CT angiography,” British Journal of Radiology, vol. 85, pp. e1282–e1292, 2012.
[20]
R. Moriwaki and F. Numano, “Takayasu arteritis: follow-up studies for 20 years,” Heart and Vessels, vol. 7, no. 1, supplement, pp. 138–145, 1992.
[21]
L. Dagna, F. Salvo, M. Tiraboschi et al., “Pentraxin-3 as a marker of disease activity in takayasu arteritis,” Annals of Internal Medicine, vol. 155, no. 7, pp. 425–433, 2011.
[22]
P. Cie?lik and A. Hrycek, “Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications,” Autoimmunity, vol. 45, no. 2, pp. 119–128, 2012.
[23]
S. S. Uppal and S. Verma, “Analysis of the clinical profile, autoimmune phenomena and T cell subsets (CD4 and CD8) in Takayasu's arteritis: a hospital-based study,” Clinical and Experimental Rheumatology, vol. 21, no. 6, supplement 32, pp. S112–S116, 2003.
[24]
J. Eichhorn, D. Sima, B. Thiele et al., “Anti-endothelial cell antibodies in Takayasu arteritis,” Circulation, vol. 94, no. 10, pp. 2396–2401, 1996.
[25]
H. Wang, J. Ma, Q. Wu, X. Luo, Z. Chen, and L. Kou, “Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis,” Journal of Vascular Surgery, vol. 53, no. 1, pp. 174–180, 2011.
[26]
I. Karapolat, M. Kalfa, G. Keser et al., “Comparison of F18 FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis,” Clinical and Experimental Rheumatology, vol. 31, no. 1, supplement 75, pp. 15–21, 2012.
[27]
D. Tezuka, G. Haraguchi, T. Ishihara et al., “Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences,” JACC: Cardiovascular Imaging, vol. 5, no. 4, pp. 422–429, 2012.
[28]
M. Fuchs, M. Briel, T. Daikeler et al., “The impact of18F-FDG PET on the management of patients with suspected large vessel vasculitis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 2, pp. 344–353, 2012.
[29]
C. Schneeweis, B. Schnackenburg, M. Stuber et al., “Delayed contrast-enhanced MRI of the coronary artery wall in takayasu arteritis,” PLoS One, vol. 7, Article ID e50655, 2012.
[30]
Y. Eshet, R. Pauzner, O. Goitein et al., “The limited role of MRI in long-term follow-up of patients with Takayasu's arteritis,” Autoimmunity Reviews, vol. 11, pp. 132–136, 2011.
[31]
M. K. Yadav, “Takayasu arteritis: clinical and CT—angiography profile of 25 patients and a brief review of literature,” Indian Heart Journal, vol. 59, no. 6, pp. 468–474, 2007.
[32]
N. Khandelwal, N. Kalra, M. K. Garg et al., “Multidetector CT angiography in Takayasu arteritis,” European Journal of Radiology, vol. 77, no. 2, pp. 369–374, 2011.
[33]
J. Hu, H. Huang, X. Zhang et al., “Stent placement for treatment of long segment (>/=80mm) carotid artery stenosis in patients with takayasu disease,” Journal of Vascular and Interventional Radiology, vol. 23, pp. 1473–1477, 2012.
[34]
D. Saadoun, M. Lambert, T. Mirault et al., “Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis a multicenter experience,” Circulation, vol. 125, no. 6, pp. 813–819, 2012.